US FDA approves Pfizer's maternal RSV vaccine to protect infants
The US FDA has approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in pregnant women during the middle of the third trimester to protect their babies. The vaccine can be given to women between 32 to 36 weeks into their pregnancy to prevent lower respiratory tract infection and severe disease in infants until they are six months old. The FDA's decision was based on data from a late-stage trial showing the vaccine to be 82% effective in preventing severe infections in infants. The CDC's approval is still pending.
Admin
0
3
The US FDA has approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in pregnant women during the middle of the third trimester to protect their babies. The vaccine can be given to women between 32 to 36 weeks into their pregnancy to prevent lower respiratory tract infection and severe disease in infants until they are six months old. The FDA's decision was based on data from a late-stage trial showing the vaccine to be 82% effective in preventing severe infections in infants. The CDC's approval is still pending. 
